Frank Martin, PhD

Biotechnology Venture Advisor

---

Frank Martin, MD is a biotechnology investor and translational immunology expert with over a decade of leadership across type 1 diabetes research, therapeutic strategy, and venture development. His work centers on advancing innovative immunology-based therapies from discovery through investment and clinical translation.

He currently serves as a Biotechnology Venture Advisor, advising emerging companies and investment funds on portfolio strategy, therapeutic evaluation, and translational development. Previously, he was a Partner at Dare Bioventures, where he supported fund strategy and early-stage biotech investments. Before that, as Senior Director of Research at Breakthrough T1D, he led portfolios focused on risk screening, beta cell survival, and regeneration to accelerate the development of disease-modifying therapies.

Dr. Martin completed a Presidential Postdoctoral Fellowship at the Novartis Institutes for Biomedical Research, specializing in early T-cell development and autoimmunity, and earned his Ph.D. in Pharmacology from Columbia University. He has been a key contributor to the T1D Fund since its inception in 2016 and serves as a strategic advisor to the Fund.